HER2 Protein: A Functional Analysis from Receptor Structure to Targeted Therapy

Author: Senior Product Manager of UA Views：11

This article focuses on the HER2 protein, systematically elaborating its domain composition as a receptor tyrosine kinase and the mechanism of dimerization-induced activation, analyzing the low-level expression of HER2 protein on normal cell membranes and the signaling imbalance caused by its overexpression on tumor cell membranes, and exploring the differential action sites of anti-HER2 antibodies and small-molecule inhibitors at the protein level as well as the protein detection basis for individualized drug therapy.

Recent Advances
Product Information

Recent Advances

HER2 Protein: A Functional Analysis from Receptor Structure to Targeted Therapy

Brief introduction: Centering on the HER2 protein, this article systematically describes its domain composition and dimerization activation mechanism as a receptor tyrosine kinase, analyzes the signal imbalance caused by the low-level expression of HER2 protein on normal cell membranes and its overexpression on tumor cell membranes, and discusses the differential action sites of anti-HER2 antibodies and small-molecule inhibitors at the protein level as well as the protein detection basis for individualized medication.

I. Domain composition and membrane receptor properties of the HER2 protein.

The HER2 protein is a member of the human epidermal growth factor receptor family and is encoded by the proto-oncogene HER2 located at chromosome 17q21. Structurally, HER2 is a single-pass transmembrane receptor tyrosine kinase, and its protein molecule can be divided into three functionally distinct modules: the extracellular ligand-binding domain, the single-pass transmembrane helix region, and the intracellular tyrosine kinase domain. The extracellular domain is responsible for forming dimers with other HER family members, the transmembrane region transmits extracellular signals into the cell, and the intracellular kinase domain undergoes trans-autophosphorylation upon receptor activation, providing docking sites for downstream adaptor proteins containing SH2 domains. A unique feature of the HER2 protein is that its extracellular domain can adopt an activated-like conformation even in the absence of ligand binding, which makes it the member of the HER family most prone to forming heterodimers and also determines the "amplifier" role of the HER2 protein in the signaling network.

II. Expression levels and functional imbalance of the HER2 protein.

In normal cells, the HER2 protein is expressed at low levels or not at all, and it plays a strictly regulated role in cell growth and differentiation. This low-expression state means that the density of HER2 protein on the cell membrane is confined to the range required for normal signal transduction. In tumor cells, however, the expression level of the HER2 protein can increase significantly due to gene amplification, resulting in a substantial increase in receptor density on the cell surface. This overexpression effect at the protein level is not merely a simple additive increase in quantity——high-density receptors markedly raise the probability of dimerization, enabling the formation of persistently activated receptor complexes even without ligand stimulation, which in turn drives cell proliferation and anti-apoptosis through the PI3K/AKT and RAS/RAF/MEK/ERK pathways. Therefore, the molecular essence of HER2-related tumors can be understood as a receptor signaling imbalance caused by uncontrolled protein expression.

III. Genetic background of HER2 protein abnormalities: an interpretation centered on the protein.

Regarding the question of whether HER2 is inherited, a clearer answer can be given from the protein perspective. The vast majority of HER2 abnormalities occur at the somatic level, that is, the overexpression or structural variation of the HER2 protein in tumor cells does not arise from germline transmission. Its abnormalities at the protein level are often related to interactions with environmental factors such as viral infection and chemical carcinogens. The clustering of breast cancer and HER2-positive expression observed in certain families is more likely related to genetic susceptibility or environmental factors shared by family members, rather than direct inheritance of a single HER2 gene. In other words, what is detected clinically is the expression status of the HER2 protein in tumor tissues, not an inheritable protein defect. This distinction is crucial for understanding the target of targeted therapy——the treatment targets the overexpressed HER2 protein on tumor cell membranes, rather than correcting some hereditary protein defect.

IV. Action sites of targeted drugs at the HER2 protein level.

For HER2-positive breast cancer patients, a variety of targeted drugs have been developed. From the protein perspective, these drugs have clearly differentiated action sites: trastuzumab and pertuzumab are both monoclonal antibodies that bind to different epitopes of the HER2 protein extracellular domain, inhibiting receptor complex formation by spatially blocking the dimerization interface, and can recruit immune cells to eliminate tumor cells through antibody-dependent cell-mediated cytotoxicity; small-molecule tyrosine kinase inhibitors such as lapatinib enter the cell and competitively bind the ATP pocket of the intracellular kinase domain, blocking receptor autophosphorylation and downstream signal activation. The two classes of drugs act on the extracellular domain and the intracellular kinase domain of the HER2 protein, respectively, forming a complementary framework of blocking dimerization from outside the protein and blocking catalytic activity from inside the protein. The selection and use of drugs should be based on the patient's specific condition and the physician's recommendations, and their core basis is precisely the detection results of the HER2 protein expression status in tumor tissues.

V. Conclusion.

As a receptor tyrosine kinase with a unique tendency toward an activated conformation in the HER family, the HER2 protein, by virtue of its three-module structure comprising the extracellular domain, transmembrane region, and intracellular kinase domain, its low-level controlled expression on normal cell membranes and the signal imbalance caused by overexpression on tumor cell membranes due to gene amplification, as well as the complementary targeted framework in which anti-HER2 antibodies act on the extracellular domain to block dimerization and small-molecule inhibitors act on the intracellular kinase domain to block catalysis, has become one of the most representative protein molecules in the fields of receptor tyrosine kinase research and tumor-targeted therapy.

In basic research and targeted drug development related to the HER2 protein, high-quality recombinant HER2 protein is a core tool for dissecting its domain functions, evaluating the binding activity of targeted drugs, and conducting species cross-reactivity studies. Mouse-derived HER2 protein shares high sequence homology with human HER2 protein and is an important tool molecule for evaluating drug efficacy and species cross-reactivity in mouse tumor models. The His tag facilitates efficient purification via immobilized metal affinity chromatography and enables detection and capture with anti-His tag antibodies. To meet the needs of HER2 protein functional research and tumor-targeted drug development, UA provides Her2/ErbB2 His Tag Protein, Mouse. This product is suitable for applications such as binding activity analysis of HER2 protein with targeted antibodies and small-molecule inhibitors, in vitro studies of HER2 protein dimerization and kinase activation mechanisms, efficacy evaluation of HER2-targeted drugs in mouse tumor models, and the establishment and validation of HER2 protein immunoassay methods.

This article is reviewed and published by the technical expert team of UA

Disclaimer: This article partially utilizes artificial intelligence assistance in its creation. If any content involves copyright or intellectual property issues, please let us know and we promise to verify and remove it as soon as possible.

Purchase recombinant protein, choose

UA protein focuses on providing various protein reagents, raw materials, and services required for drug research and development, cell therapy, gene therapy, and basic scientific research, including drug target proteins, immune checkpoint proteins, cytokines, tool enzymes, customized protein expression, and full-length transmembrane protein development. Nanjing Univ is committed to providing customers with high-quality products and professional services, and building a High-tech Biological Enterprise with International Competitiveness.

Buy antibodiesFind UA www.ua-bio.com | 15 years of protein development experience

Nanjing UNIV Biotechnology Co., Ltd. Email：order@ua-bio.com Phone：+86-25-56221161

more products

Product Information

The Last The Next